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New and effective treatments for advanced gastric cancer are urgently needed. 
Cyclins E and D1 form a complex with cyclin-dependent kinase 2 (CDK2), 4 or 6, 
thereby regulating G1-S transition. The G1-S regulatory genes encoding cyclin E 
(CCNE1), cyclin D1 (CCND1) and CDK6 (CDK6) are frequently amplified in gastric 
cancer and may therefore influence molecular targeted therapies against ERBB2 or 
EGFR when co-amplified. A total of 179 formalin-fixed and paraffin-embedded gastric 
cancer specimens were examined for these gene amplifications by multiplex 
ligation-dependent probe amplification (MLPA) and fluorescence in situ hybridization 
(FISH). Amplification of at least one G1-S regulatory gene was found in 35 tumors 
(CCNE1 amplification, 15% of samples; CCND1, 6%; CDK6, 1%). In 13 of the 35 
tumors, dual-color FISH identified co-amplification of the G1-S regulatory genes with 
ERBB2, EGFR and/or KRAS in single cancer nuclei. The observation that cells with 
G1-S regulatory gene amplification contained clonal subpopulations with 
co-amplification of ERBB2, EGFR or KRAS in five early and three advanced cancers 
suggests that amplification of the G1-S regulatory genes represents an early event which 
precedes ERBB2, EGFR or KRAS amplification. Amplified CCNE1, CCND1 and CDK6 
in advanced gastric cancer may be potentially useful as direct targets for molecular 
therapy, or for combination therapy with ERBB2 or EGFR inhibitors. MLPA could be a 












Gastric adenocarcinoma is the fourth most common cancer and the third leading cause 
of cancer-associated death worldwide [1]. In the initial stages of gastric adenocarcinoma, 
such as the early gastric carcinomas as defined by the Japanese Research Society for 
Gastric Cancer [2], the carcinoma is confined to the mucosa and the submucosa. These 
early tumors are usually endoscopically or surgically resectable and can be cured [3]. In 
contrast, a poor prognosis is associated with advanced gastric cancers that have 
penetrated the muscle layer [2], metastasized and/or developed an inoperable carcinoma. 
Thus, novel therapeutic modalities are urgently needed for the treatment of late-stage 
gastric carcinomas. 
Under normal circumstances, growth factor signaling leads to the expression of 
cyclin D1 and its complexing with cyclin-dependent kinase 4 (CDK4) or CDK6. 
Following accumulation of active cyclin D1/CDK4 or CyclinD1/CDK6, CDK2 in 
combination with cyclin E then accumulates to facilitate the transition from G1 to S 
phase by phosphorylation of downstream targets, including the tumor suppressor RB [4]. 
It is generally accepted that gene amplification is the major mechanism of cyclin D1 and 
E overexpression. However, another possible mechanism for accumulation of cyclin E 
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is alterations in its degradation pathway due to mutations in hCDC4. [5, 6]. 
Amplified genes encoding receptor tyrosine kinases (RTK) such as ERBB2, 
EGFR, FGFR2 and MET are established or potential targets of molecular therapy in 
advanced gastric cancers. In addition to RTK genes, recent comprehensive genomic 
analyses of copy number alterations using a high-resolution single nucleotide 
polymorphism array (SNP) [7], along with oligonucleotide array comparative genomic 
hybridization (aCGH) [8], have shown that the genes encoding cyclin E (CCNE1), 
cyclin D1 (CCND1) and CDK6 (CDK6) are frequently amplified in gastric cancer. 
Co-amplification of CCNE1 or CCND1 with ERBB2 reportedly reduced the anti-tumor 
effects of trastuzumab, a monoclonal antibody against ERBB2, in gastric and breast 
cancers [9]. 
Multiplex ligation-dependent probe amplification (MLPA) is a new, 
high-resolution method for the detection of numerous copy number variations in 
genomic sequences in a single reaction. Using MLPA, the aims of this study were to 
determine the gene amplification status of CCNE1, CCND1 and CDK6 in gastric cancer 






Materials and Methods 
 
Patients and control cell lines 
A total of 179 patients with gastric adenocarcinoma (84 early- and 95 advanced-stage 
tumors) who underwent surgery at the Department of Surgery in Kanazawa University 
Hospital between 2013 and 2015 contributed tumor specimens to this study. This 
laboratory study was approved by the Medical Ethics Committee of Kanazawa 
University (Approval No. 181), and written informed consent was obtained from all 
patients.  
 Cancer staging was performed according to the TNM cancer staging system of 
the American Joint Committee on Cancer [10]. The World Health Organization 
Classification of Tumours [11] was used to determine histological classification. Serial 
sections cut from representative formalin-fixed and paraffin-embedded cancer 
specimens were used for hematoxylin and eosin (H-E) staining, MLPA, fluorescence in 
situ hybridization (FISH) and immunohistochemistry (IHC). When a primary tumor was 
positive for gene amplification of CCNE1, CCND1, CDK6, ERBB2, EGFR and/or 
KRAS, samples of nodal metastatic tumors, if any, were also examined for amplification 
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of the positive gene(s) by FISH. The cell lines MKN7, A431 (both from Riken Cell 
Bank, Tsukuba, Japan) and SNU5 (American Type Culture Collection, Rockville, MD) 




  Cancer-enriched 6 µm-thick serial section that excluded non-neoplastic cells were 
selected by comparison to the adjacent H-E-stained section. DNA was manually 
extracted from each selected section using proteinase K (Roche Diagnostics, Manheim, 
Germany) according to the manufacturer’s protocol (MRC-Holland, Amsterdam, The 
Netherlands).  
DNA was subjected to MLPA using the SALSA MLPA probemix P458-B1 
Gastric Cancer kit (MRC-Holland), which contains two to three probes for each of 16 
genes including CCNE1, CCND1, CDK6, KRAS, ERBB2, and EGFR. The resulting 
polymerase chain reaction (PCR) products were separated on an ABI-310 capillary 
sequencer (Applied Biosystems, Foster City, CA) and the results interpreted with 
GeneMapper software (Applied Biosystems). Data analysis was performed with 
Coffalyser MLPA-DAT software version 9.4 (MRC-Holland) to normalize peak values. 
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Average peak values below 0.7 were defined as ‘lost’; between 0.7 and 1.3 as ‘normal’; 
between 1.3 and 2.0 as ‘gain’; and above 2.0 as ‘amplified’, as previously 
established.[12, 13] Both ‘amplified’ and ‘gain’ results were considered MLPA-positive 




IHC for cyclin E, cyclin D, ERBB2 and EGFR was performed on representative 
sections of all tumors. IHC detection of CDK6 and KRAS was also attempted but 
yielded unsatisfactory results. The antibodies used were a mouse monoclonal antibody 
against cyclin E (sc-247; Santa Cruz Biotech, Dallas, TX; working dilution, 1:200), a 
rabbit monoclonal antibody against cyclin D1 (SP4; Nichirei, Tokyo, Japan; prediluted), 
a polyclonal antibody against the internal domain of human ERBB2 (Nichirei; working 
dilution, 1:400), and mouse monoclonal antibodies against the external domain of the 
human EGFR (Novocastra Lab, Newcastle, UK; working dilution, 1:20). Antibody 
binding was visualized using the LSABTM system (Dako, Glostrup, Denmark).  
For evaluation of cyclin E and D1 staining, only nuclear immunostaining in each 
tumor section was scored using a four-tier system: 0, no staining; 1+, staining with an 
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intensity and frequency similar to the pattern occasionally observed in the neck zone of 
normal gastric mucosa; 2+, intermediate staining intensity; 3+, intense staining in more 
than 80% of tumor cells. Immunostaining of ERBB2 and EGFR was scored using a 
four-tier system (0, 1+, 2+, 3+) according to the criteria recommended by Dako for the 
HercepTestTM, except that the number of positive cells was not considered. Staining was 
evaluated by two observers (TO and AO) and discordance was resolved by discussion. 
Tumors with 2+ and 3+ staining were considered positive, and were further examined 
for amplification of the corresponding gene(s) by FISH. 
 
FISH 
The FISH probes used in this study were acquired from BACPAC Resources (Oakland, 
CA) and are summarized in Table 1. The probes were labeled with SpectrumOrangeTM 
or SpectrumGreenTM using a nick translation kit (Abbott Laboratories, Abbott Park, IL). 
For quantification of gene amplification, a pericentromeric probe (Abbott) specific to 
each gene’s chromosome, or a BAC probe specific to sequences near the particular gene, 
was co-hybridized to standardize the chromosome number. Tumors demonstrating 
co-amplification of multiple genes were further examined by simultaneous 
hybridization using two probes to the genes that were labeled with different fluorescent 
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markers, in order to assess the co-existence of the amplified genes in single nuclei or 
single amplicons. 
Removal of protein from the tissue sections, denaturation, hybridization and 
post-hybridization washing were performed as described previously [13]. The tissue 
sections were counterstained with DAPI II (Abbott) and examined using a fluorescence 
microscope (Olympus, Tokyo, Japan) equipped with a Triple Bandpass Filter set 
(Abbott) for DAPI II, SpectrumOrangeTM and SpectrumGreenTM. Scoring and 
evaluation of FISH slides was performed manually by counting the target gene signals 
and control signals in 20 tumor cell nuclei per sample. Gene amplification was 
determined according to the American Society of Clinical Oncology/College of 
American Pathologists criteria for ERBB2 amplification except that the number of 
positive cells was not considered in this study [14]. Low-level amplification was 
defined as two or more additional copies of genes compared to control signals. In cases 
of apparent intratumoral heterogeneity in gene amplification, the fractions (%) of tumor 
cells positive for gene amplification were scored and categorized into broad tiers of 





Mutations in exons 8 and 12 of hCDC4, which represent the locations of most reported 
hCDC4 mutations in gastric carcinomas [15] were analyzed by direct sequencing in 
tumors with overexpression but not amplification of CCNE1. In tumors with KRAS 
amplification, codons 12, 13 and 61 were also analyzed, as point mutations have been 
reported only in these locations. The PCR conditions for amplification of exon-specific 




The association between gene amplification and early or advanced cancer was analyzed 





All 179 gastric adenocarcinoma tissue samples and all three cell lines were successfully 
analyzed by MLPA for the expression of 16 genes. The status of each gene in each of 
the 179 tumors was categorized as ‘amplified’, ‘gain’ or ‘normal’ based on its mean 
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MLPA peak value. There were no instances of ‘lost’ genes. Subsequent FISH analyses 
confirmed gene amplification in 45 of the 49 (92%) tumors that were classified as 
‘amplified’, and 48 of the 148 (32%) tumors that were classified as ‘gain’, for any of 
these 13 genes. However, gene amplification of FGFR1, GATA4 and GATA6 was not observed in 
any tumor. The number of tumors categorized as ‘amplified’ or ‘gain’ for specific genes 
by MLPA analysis and FISH-proven amplification is summarized in Table 1.  
 
IHC analysis 
Analysis of the expression of cyclin E and cyclin D1 using IHC identified positive 
immunostaining for these proteins in 58 and 59 of the 179 tumors, respectively. IHC 
analysis of ERBB2 and EGFR expression was also performed. By combining the results 
of IHC and subsequent FISH analysis, gene amplification of CCNE1, CCND1, ERBB2 
and EGFR was observed among tumors with ‘normal’ MLPA values, as shown in Table 
1. A total of 20 tumors had positive immunostaining for cyclin E but were negative for 
amplification of its gene CCNE1. Although hCDC was successfully sequenced in all of 






The same 16 genes that were analyzed by MLPA were also examined with FISH. In 
FISH images, most of the samples with highly amplified genes displayed either tightly 
clustered or numerous scattered signals, suggesting amplicons in homogeneously 
staining regions (HSRs) or double minute chromosomes (DMs), respectively [16]. 
Cancer nuclei with co-localization of an amplified gene and the amplified centromeric 
lesion on which the gene is located, which results in a yellow fusion signal [17], were 
rarely observed. FISH analysis of the cell lines used as positive controls for gene 
amplification of CCNE1, CDK6 and CCND1 indicated HSR-type amplification of 
CCNE1 and CDK6 in MKN7 and SNU5 cells, respectively, and low-level amplification 
of CCND1 in A431 cells, as shown in Suppl. Fig. 1. 
FISH analysis indicated that CCNE1 was amplified in 12 of the 84 (14%) early 
gastric cancer tumors and in 14 of the 95 (15%) advanced tumors, and was the most 
frequently amplified gene among the 16 genes examined. Amplification of CCND1 and 
CDK6 was found in ten and two tumors, respectively. Table 2 shows the 
clinicopathological characteristics of the 35 tumors with gene amplification of CCNE1, 
CCND1 and/or CDK6. No significant differences between early and advanced cancers 
were observed in the amplification frequencies of CCNE1, CCND1 or CDK6 (p=0.87). 
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FISH was further used to determine co-amplification of genes within the tumors. 
Co-amplification of CCNE1 and CCND1 was found in three early gastric cancers 
(Cases 1, 12 and 15) (Table 2); CCNE1-amplified cancer cells and CCND1-amplified 
cells were present in different areas of these cancers. However, no cancer cell had 
simultaneous amplification of these two genes, as shown in Fig. 1. Analysis of 19 
advanced gastric cancer tumors indicated that CCNE1, CCND1 or CDK6 was amplified 
in each tumor and that, in most instances, the majority of cells demonstrated the gene 
amplification. 
Co-amplification of CCNE1, CCND1 and/or CDK6 with ERBB2, EGFR and/or 
KRAS in various combinations was found in 18 out of 35 tumors, as shown in Table 2. 
More precise examination by dual-color FISH revealed that these co-amplifications 
occurred in single cancer nuclei in five early gastric cancers (Cases 3, 5-7 and 14) and 
in eight advanced gastric cancers (Cases 18, 23, 24, 26-28, 34 and 35). Case 5 was a 
non-invasive mucosal adenocarcinoma in which almost all cancer cells had 
amplification of CCND1 and three separate areas of the tumor also had co-amplification 
of ERBB2, EGFR and KRAS, as shown in Fig. 2. The other two mucosal cancers, which 
were predominantly composed of CCNE1-amplified cells (Case 3) or CDK6-amplified 
cells (Case 6), demonstrated co-amplified EGFR in only a fraction of the tumors. Two 
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submucosal invasive cancers that consisted exclusively of CCNE1-amplified cells (Case 
7) or CCND1-amplified cells (Case 14) had a clonal subpopulation of ERBB2-amplified 
and EGFR-amplified cells, respectively. 
In the remaining five early gastric cancer tumors (Cases 2, 10, 13, 15 and 16), 
gene amplification of the cyclins and RTKs occurred in different cells; however, in three 
tumors (Cases 2, 10 and 13) the cells with amplified cyclins and those with amplified 
RTKs were located adjacent to each other. Co-amplification of one of the G1-S 
regulatory genes and ERBB2, EGFR and/or KRAS was found in eight advanced gastric 
cancer tumors; however, due to the large size of the tumors, the precise distribution of 
the amplified cells could only be determined in three tumors (Cases 18, 28 and 34). 
Case 28 consisted predominantly of CCNE1-amplified cells but had a small area with 
co-amplified EGFR. In Case 18, cancer cells that had co-amplified ERBB2 were found 
to occupy small areas of the tumor, which was mostly composed of CCND1-amplified 
cells. Case 34 predominantly composed of CCND1-amplified cells showed two small 
subclonal populations of co-amplified CCND1 and ERBB2, and CCND1 and EGFR in 
the vicinity (Fig. 3A&B) 
Although Case 23 had a KRAS-amplified clonal subpopulation that was distinct 
from the majority CCNE1-amplified population, Case 27 demonstrated co-amplification 
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of KRAS and CCNE1 in single nuclei. Direct sequencing did not detect any point 
mutations in KRAS codons 12, 13 or 61 in either of these two tumors, the tumor of Case 
5, or an early gastric cancer tumor. Dual-color FISH analysis of the co-amplified genes 
showed that the fluorescent signals corresponding to the amplified genes were separated, 
thus suggesting that they were located on different amplicons. In Case 35, however, 
CDK6 signals and ERBB2 signals always overlapped, which suggested that these two 
genes were located in the same amplicons in most cancer cells (Fig. 3C).  
Among the 19 cases of advanced gastric cancer with gene amplification of the 
G1-S regulatory genes in the primary tumor, 15 cases had lymph node metastasis. FISH 
analysis showed that the gene amplification pattern was consistent between the primary 





In the present study, gene amplification of CCNE1 was the most frequent amplification 
found among the 16 genes examined in tumor samples from patients with gastric 
cancers, with CCNE1 amplification confirmed by FISH analysis in 26 out of 179 (15%) 
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tumor samples. Amplification of CCND1 and CDK6 was found in ten (6%) and two 
(1%) gastric cancer tumor samples, respectively.  
We did not observe co-amplification of the G1-S regulatory genes CCNE1, 
CCND1 and CDK6 in single tumor cells. However, three early gastric cancer tumors 
contained CCNE1-amplified cells located in the vicinity of CCND1-amplified cells. The 
lack of observed co-amplification in single cells is likely due to only one perturbation in 
early G1 control being sufficient for gastric carcinogenesis. [18]. KRAS is a 
downstream mediator of RTK signaling and is activated by point mutations in many 
cancers. However, these activating point mutations are strikingly rare in gastric cancers 
compared to other gastrointestinal cancers.[7] Our results show that gene amplification 
of KRAS occurred with greater frequency than expected in gastric cancers, and was 
mutually exclusive with RTK gene amplification.  
In the present study, more than half of the tumors with amplification of at least 
one G1-S regulatory gene had co-amplification of ERBB2, EGFR and/or KRAS (10/16 
early and 8/19 advanced cancers). This co-amplification occurred in single nuclei in five 
of the early cancers and in all eight of the advanced cancers. Co-amplification of these 
genes in various frequencies has been reported in studies of gastric cancers using SNP, 
DNA microarray or FISH analyses [19-21]. However, our use of dual-color FISH 
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enabled us to clearly demonstrate for the first time that these co-amplifications can 
occur in single cancer nuclei.  
It remains to be clarified why these co-amplified genes, which were originally 
located on different chromosomes or on different arms of the same chromosome (e.g., 
CDK6 and EGFR), are preferentially co-amplified. We observed in five early gastric 
cancers (including three intramucosal cancers) and at least three advanced cancers that 
cells with amplification of CCNE1, CCND1 or CDK6 contained clonal subpopulations 
of concomitantly amplified ERBB2, EGFR or KRAS. This combination of cancer 
staging, histological typing and gene amplification patterns suggests that genetic 
instability initiates the amplification of G1-S regulatory genes during the preclinical 
stage of non-invasive and/or mucosal cancers. The resulting deregulation of the cell 
cycle may then lead to further genomic instability, driving ERBB2 or EGFR gene 
amplification in these tumors. Subsequent selection then produces separated, 
heterogeneous clonal subpopulations, as shown in Fig. 4. Unlike RTK genes, the G1-S 
regulatory genes are likely necessary for later tumor progression. Therefore, these genes 
are maintained in large populations within most advanced cancers and metastatic foci. 
This observation supports possible use of the cyclins and CDK6 as targets of molecular 
therapy. However, cyclins are generally regarded as difficult to target directly with 
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therapies, as they lack intrinsic enzymatic activity and are intracellular. Thus, their 
functionality may most readily be targeted via their partner kinases, i.e., CDK2 for 
cyclin E [22] and CDK4 or CDK6 for cyclin D1 [21]. Currently, there are an estimated 
ten small-molecule pan-CDK inhibitors or highly selective inhibitors in clinical trials 
for various cancer types [23].  
Information regarding the co-amplification of CCNE1 and CCND1 may be 
further useful for current molecular targeted therapies. One study of patients with 
ERBB2-positive gastric cancer found that individuals with concomitant amplification of 
CCNE1 demonstrated a significantly shorter progression-free survival than those 
without concomitant CCNE1 amplification [20]. CCND1 amplification has been linked 
to resistance to the EGFR inhibitor gefitinib in experimental models of head and neck 
cancer [24] [25].- 
In molecular targeting therapy, it is critical to establish a feasible screening 
method in order to identify eligible patients. MLPA is, compared to SNP, aCGH and 
next-generation sequencing techniques, a relatively cheap, and easy–to-perform method 
that allows simultaneous detection of multiple gene copy number aberrations in small 
amount of fragments DNA derived from formalin-fixed material [26]. It is, however, 
based on PCR and averages many different cells, thus theoretically validation by 
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morphological method, such as FISH is mandatory. The present study not only showed 
MLPA can be used as an efficient screening method for searching tumors with most 
gene amplification but also in several genes the confirmatory FISH may be unnecessary 
by setting approximate threshholds.  
In conclusion, the common and relatively homogeneous amplification of 
CCNE1, CCND1, and CDK6 in primary and metastatic nodes of advanced gastric 
cancer may offer direct targets for molecular therapy. Co-amplification of these genes 
with ERBB2 or EGFR may also render them targets for combination therapy with 
ERBB2 or EGFR inhibitors. MLPA is a useful tool to identify patients who would 
benefit from such therapies. 






Table 1.  
Results of the MLPA and FISH analyses of tumor samples from 179 gastric cancer 
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patients. Values in parentheses are the numbers of tumors with gene amplification 
verified by FISH. 
 
Table 2. 
Characteristics of gastric cancer tumors with amplification of CCNE1, CCND1 and/or 
CDK6. ‘Cases 1-16 are early gastric cancers; Cases 17-35, advanced gastric cancers. 
Abbreviations: co-amp, co-amplification of a gene and the centromeric lesion in HSR; 
DCS, combination chemotherapy with docetaxel, cisplatin and S-1; DM, double-minute 
chromosome-type amplification; DOC, docetaxel; HSR, homogeneously staining 
region-type amplification; low amp, low-level amplification; mixed, mixed carcinoma; 
MP, muscularis propria; NE, neuroendocrine carcinoma; por, poorly cohesive 
adenocarcinoma; SE, serosa exposed; sig, signet-ring cell carcinoma; SM, submucosa; 
SS, subserosa; tub, tubular adenocarcinoma.  
 
Fig. 1. 
A representative intramucosal gastric cancer tumor sample with co-amplification of 
CCNE1 and CCND1 (Case 1). (A) Hematoxylin and eosin stain. The areas indicated as 
(I) and (II) show overexpression and amplification of cyclins E and D1, respectively. 
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The region enclosed by the black rectangle labelled (B) corresponds to the fields in 
panels (B) and (D); the black rectangle labelled (C) corresponds to panels (C) and (E). 
(B and C) Immunohistochemistry of cyclin E (B) and cyclin D1 (C). (D and E) 
Dual-color FISH analysis: orange fluorescence, CCNE1; green fluorescence, CCND1. 
 
Fig. 2. 
Early gastric cancer tumor with amplification of CCND1 (Case 5). This intramucosal 
cancer with homogenously amplified CCND1 contained small, separated areas with 
co-amplification of ERBB2, KRAS or EGFR. (A) Hematoxylin and eosin stain. (B, C 
and E) Immunohistochemistry showed homogeneous staining of cyclin D1 (B) and 
indicated that the small, separated areas were positive for ERBB2 (C) and EGFR (E). 
(D, F, & G) The region enclosed by the black rectangle labelled D in panel (C) 
corresponds to panel (D), and in panel (E) the rectangles labelled F and G correspond to 
panels (F) and (G), respectively. FISH analysis showed that ERBB2- and 
EGFR-overexpressing cells had amplification of the corresponding gene (D and G, 
respectively) and focal KRAS-amplification (F). In (D), orange fluorescence 
corresponded to ERBB2; green fluorescence, CCND1; (F) orange fluorescence, KRAS; 





 Fig. 3. 
Advanced gastric cancer tumors with amplified CCND1 (Case 34, panels A and B) or 
CDK6 (Case 35, C). (A, B) Case 34 had an area of CCND1 amplification where 
amplification of ERBB2 and EGFR was observed in nearby cells, but their amplification 
was mutually exclusive. Adjacent sections were alternatively stained for ERBB2 (A) 
and EGFR (B) using immunohistochemistry. Dual-color FISH showed co-amplification 
of CCND1 (orange signals) and ERBB2 (green signals) (A, inset) and co-amplification 
of CCND1 (orange signals) and EGFR (green signals) (B, inset). (C) Dual-color FISH 
analysis of Case 35 demonstrated overlap (yellow) of amplified HSR-like signals for 
CDK6 (orange) and ERBB2 (green).  
 
Fig. 4. 
A potential mechanism for the gene co-amplification observed in gastric cancer. This 
model speculates that gene amplification of CCNE1, CCND1 and CDK6 occurs in early 
gastric carcinogenesis. Such amplification induces genomic instability, which drives 
ERBB2, EGFR or KRAS gene amplification. The 35 tumors with CCNE1, CCND1 and 
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CDK6 are sorted according to this pathway. The numbers in normal font and the 
numbers in bold font correspond to the case numbers of the early gastric cancers and the 
advanced gastric cancers, respectively. Circles: amplified CCNE1, CCND1 or CDK6; 
rectangles: amplified ERBB2, EGFR or KRAS. 
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No. of No. of No. of  'normal' tumors Frequency of tumors 
Name of genes Chromosomal locus of gene FISH probe amplified ' tumors gain ' tumors with IHC-positive with gene amplification
CCNE1 19p12  RP11-345J21 16 (16) 11 (7) 31(3) 15% (26)
CCND1 11q13.3  RP11-775J10 5 (5) 7 (3) 47 (2) 6% (10)
CDK6 7q21.2 RP11-316P4 2 (2) 8 (0) 1% (2)
ERBB2 17q12 RP11-62N23 6 (6) 10 (7) 4 (4) 9%(17)
EGFR 7p11.2  RP11-339F13 2 (1) 9 (3) 10 (9) 7% (13)
MET 7q31.2 RP11-75I20 1 (1) 9 (4) 3% (5)
FGFR2 10q26.13  RP11-62L18 1(1) 4 (2) 2% (3)
KRAS 12p12.1  RP11-1119I8 2 (2) 11 (2) 2% (4)
MYC 8q24.21   RP11-440N18 8 (6) 20 (10) 9% (16)
PTP4A3 8q24.3 RP11-240D7 1 (1) 15 (8) 5% (9)
PIK3CA 3q26.32   RP11-1115H8 0 6 (1) 0.5% (1)
KLF5 13q22.1 RP11-179I20 2 (2) 16 (0) 1% (2)
TOP2A 17q21.2 RP11-48O10 2 (2) 6 (1) 2% (3)
FGFR1 8p11.23    RP11-148D21 0 4 (0) 0
GATA4 8p23.1 RP11-235I4 1 (0) 5 (0) 0
GATA6 18q11.2 RP11-18K7 1 (0) 7 (0) 0
Values in parentheses are the numbers of tumors with gene amplification validated by FISH.
Table 1 Results of the MLPA and FISH analyses of 179 gastric cancers








d therapy CCNE1 CCND1 CDK6 ERBB2 EGFR KRAS in metastatic nodes
















4 0-IIc tub non 0 HSR (>70) 
e -
5


















8 0-IIa+IIc tub SM IA HSR & low Amp (>70) 
e -
9 0-IIc tub SM IA HSR (>70) 
e -
10




11 0-IIb+IIc tub SM IA HSR (>70)
 e -
12 0-IIa+IIc tub SM IA HSR (>70) 
e -
13









15 0-III tub SM IB Low amp (<10) 
g








17 2 tub MP IB HSR (>70) 
e -
18




19 2 tub MP IIA HSR (>70)
 e CCND1
20 1 tub SS IIA Low amp (10-30)
 f -
21 3 por SS IIA Low amp (30-50) 
f -
22 2 mixed SS IIIA HSR (>70) 
e CCNE1 
23







a 2 tub SS IIIB HSR (>70)
 e
HSR & Low amp (>70) 
e CCNE1, ERBB2, 
25 3 mixed SS IIIB DCS HSR (>70) 
e CCNE1
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a 3 tub SE IIIB HSR  (>70)
 e HSR, (<10) g CCNE1 
29 3 por SE IIIB HSR (>70) 
e CCNE1
30 3 tub SE IIIC DCS Low amp (50-70) 
g CCNE1
31 4 mixed SE IV HSR (>70)
 e Failed
32 2 NE SE IV DCS HSR (>70)
 e CCNE1
33 5 mixed SE IV co-amp, (>70) 
f CCNE 1
34
a 3 mixed SE IV DCS HSR (30-50) 
g DM      (<10) g HSR   ( <10) g CCND1, EGFR
35
a 4 tub SE IV HSR (>70) 
e HSR (>70)  e CDK6, ERBB2
Cases 1-16, early gastric cancers; cases 17-35, advanced gastric cancers.
Abbreviations: tub, tubular adenocarcinoma; mixed, mixed carcinoma; sig, signet-ring cell carcinoma; por, poorly cohesive adenocarcinoma; NE, neuroendocrine carcinoma; SM, submucosa; MP, muscularis propria; SS, subserosa; SE, serosa
exposed; DCS, combination chemotherapy with docetaxel, cisplatin and S-1; DOC, docetaxel; HSR, homogeneously staining region type amplification; DM, double minute chromosome type amplification; co-amp, co-amplification of a gene and
the centromeric lesion in HSR; Low amp, low-level amplification.
Table 2 Gastric cancers with gene amplification of CCNE1 , CCND1 , and/or CDK6
a: Co-amplification of at least of one of CCNE1, CCND1, or CDK6 with at least one of ERBB2, EGFR, or KRAS in single cancer nuclei.
b: The co-amplification of the cyclins and RTKs occurred in different cells, however, in they were located adjacent to each other.
c: Accoding to The World Health Organization Classification of Tumors
17
d: According to the TNM cancer staging system of the American Joint Committee of Cancer.
16
e: 'amplified' by MLPA.
f: 'gained' by MLPA.
g: 'normal' by MLPA.




